Fingertip Pulse Oximeter (OEM / CE/FDA Class II)

CE MDR vs. MDD: What Changed for Class IIa Devices

The EU Medical Device Regulation (MDR) 2017/745 fully replaced the Medical Devices Directive (MDD) 93/42/EEC in May 2021, with a grace period for MDD-certified devices expiring in stages through 2024–2027 depending on risk class.

For pulse oximeters classified as Class IIa under MDR (Rule 10: devices for monitoring vital physiological parameters), the practical changes from MDD are significant. Under MDD, a manufacturer could self-declare conformity against harmonized EN standards with relatively minimal documentation. Under MDR, Class IIa devices require involvement of a Notified Body (NB) for the Quality Management System (Annex IX) or the type examination route (Annex X). The NB must review the technical documentation including clinical evaluation, risk management (ISO 14971), and post-market surveillance plan.

The Unique Device Identification (UDI) requirement under MDR is also new: every device must carry a UDI-DI (device identifier, static per model) and a UDI-PI (production identifier, lot or serial-specific), registered in the EUDAMED database. Chinese manufacturers exporting to the EU must register in EUDAMED as the legal manufacturer or appoint an EU Authorized Representative (AR) who registers on their behalf.

Notified Body costs for a Class IIa pulse oximeter QMS audit (Annex IX) range from €10,000–€25,000 for initial certification plus €3,000–€8,000 annually for surveillance audits. Select an NB early: as of 2024, only ~40 NBs are designated under MDR (versus ~80 under MDD), and backlogs of 12–18 months are common. BSI, TÜV SÜD, and SGS are the most widely used by Chinese medical device manufacturers for EU market access.

FDA 510(k) for Pulse Oximeters: Predicate Selection and Testing

Pulse oximeters for clinical use are regulated by FDA as Class II devices under 21 CFR 870.2700. The 510(k) pathway requires demonstrating substantial equivalence to a legally marketed predicate device.

The performance standard governing 510(k) submissions for pulse oximeters is ISO 80601-2-61:2019 (medical electrical equipment — particular requirements for the safety and essential performance of pulse oximeter equipment). Key testing required under this standard:

• Bench accuracy testing: SpO2 accuracy (A_RMS) must be ≤3% at 70–100% saturation range for clinical-grade devices. Testing requires a CO-oximeter blood gas analyzer as the reference standard. Bench testing alone using optical models or breathing simulators is not sufficient — FDA requires tissue-equivalent phantom testing data at minimum, and often clinical data.
• Clinical study: For non-motion applications at <80% SpO2 (the critical low-saturation range), FDA expects clinical validation with human subjects at induced low saturation (controlled hypoxia studies). Typically 10 healthy subjects with measurements spread across 70–100% SpO2 range. These studies require an IRB-approved protocol and a specialized clinical facility.

Predicate device selection: search the FDA 510(k) database for cleared pulse oximeters in product code DQA (oximeter, ear/fingertip). Selecting a predicate with similar technology (fingertip, OLED display, single-wavelength) simplifies the substantial equivalence argument. 510(k) total timeline is typically 90 days for SE (substantially equivalent) decisions on straightforward devices, but can extend to 12 months if FDA issues additional information requests. Third-party review program (accredited persons) can reduce review time for this device type. Total cost with a regulatory consultant: $50,000–$150,000.

Clinical-Grade vs. Wellness-Grade: Factory Claims and What They Mean

The majority of Chinese pulse oximeter factories produce wellness-grade devices that do not meet the accuracy requirements of ISO 80601-2-61. The distinction matters because CE marking alone does not indicate clinical accuracy — a device can carry CE marking under the MDR by meeting the essential requirements but still fail clinical accuracy testing at <80% SpO2.

Common factory claim: “accuracy ±2% at 70–100%.” The accuracy specification is meaningful only if supported by a test report covering the full saturation range, including the low-saturation region (<80%), which is where most wellness devices perform poorly. Red light photoplethysmography (PPG) accuracy degrades significantly at low saturation due to the optical absorption characteristics of deoxygenated hemoglobin. Request the actual ISO 80601-2-61 A_RMS test report from an ISO 17025-accredited laboratory — not the factory’s internal QC report.

For buyers sourcing OEM oximeters for B2B distribution to medical facilities or for use in diagnostic claims, the minimum requirement is an ISO 80601-2-61 validation report from a third-party lab covering 70–100% SpO2. For consumer wellness products (labeled “not for medical use”), the clinical testing requirements are lower, but marketing claims must be carefully reviewed against FDA and FTC guidance to avoid misbranding.